Reported Earnings • Jun 12
First quarter 2027 earnings released: US$0.10 loss per share (vs US$0.13 loss in 1Q 2026) First quarter 2027 results: US$0.10 loss per share (improved from US$0.13 loss in 1Q 2026). Revenue: US$433.4k (down 35% from 1Q 2026). Net loss: US$1.24m (loss narrowed 11% from 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • May 16
Active Intelligence and Nutriband Inc. Showcases Expanding Ai Wellness Product Portfolio and Announces New June Product Launches At Ecrm Conference Nutriband Inc. and its wholly owned subsidiary Active Intelligence announced its participation in the upcoming ECRM conference taking place in June 2026, where the Company will showcase its latest AI-branded product portfolio to buyers and executives from some of the nation’s largest retail and healthcare organizations. During the conference, Active Intelligence is scheduled to meet with category buyers and decision-makers representing major national retailers and distributors, including Walmart, Walgreens, Amazon, Cardinal Health, and numerous additional retail, pharmacy, healthcare, and e-commerce channels. The Company will feature its growing AI Tape product line, which continues to gain traction within the wellness, recovery, and athletic performance categories. In addition, Active Intelligence plans to introduce several new products scheduled for launch in June 2026, including: AI Performance Tape—a next-generation kinesiology and recovery product designed to support athletic performance, mobility, muscle recovery, and active lifestyles; AI Energy Patches—innovative wearable wellness patches formulated to support energy, focus, and daily performance; and AI Sleep—a wellness-focused solution developed to support relaxation, recovery, and improved sleep quality. The Company believes these new additions further strengthen its position within the rapidly expanding global wellness market and broaden its opportunities for national retail placement across multiple high-growth consumer categories. Reported Earnings • May 05
Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2026 results: US$2.58 loss per share (further deteriorated from US$0.99 loss in FY 2025). Revenue: US$2.04m (down 4.8% from FY 2025). Net loss: US$30.0m (loss widened 187% from FY 2025). Revenue missed analyst estimates by 25%. Earnings per share (EPS) exceeded analyst estimates by 58%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. 
